Ectopic ACTH- or CRH-producing tumors and Cushing’s syndrome
in: Cushing Syndrome: History, Diagnosis and Treatment, Elsevier, pp.193-207, 2026
- Publication Type: Book Chapter / Chapter Research Book
- Publication Date: 2026
- Doi Number: 10.1016/b978-0-323-96100-4.00002-8
- Publisher: Elsevier
- Page Numbers: pp.193-207
- Keywords: ACTH, CRH, Ectopic Cushing’s syndrome, Immunohistochemistry, Neuroendocrine neoplasm, Neuronal neoplasm
- Ondokuz Mayıs University Affiliated: Yes
Abstract
This chapter provides an update on the clinicopathological correlates of ectopic ACTH (adrenocorticotropic hormone)- and CRH (corticotropin-releasing hormone)-producing tumors manifesting with Cushing’s syndrome (CS). In addition to clinical, biochemical, and radiological findings, pathological examination is critical in diagnosing CS. Various tumors with ectopic ACTH/CRH production have been described. The pathological classification of these tumors is essential for the clinical management of patients with ectopic CS (ECS). A significant portion of these tumors are neuroendocrine neoplasms (NENs) that arise from a variety of anatomical sites. ECS is most frequently caused by ACTH-producing epithelial NENs in the lungs, mediastinum, pancreas, and thyroid, as well as nonepithelial NENs originating from extra-adrenal paraganglia or the adrenal medulla. Particularly, small cell lung neuroendocrine carcinoma, pancreatic NENs, thymic NENs, pheochromocytoma and paraganglioma, and medullary thyroid carcinoma account for the vast majority of ECS. Less than 1% of cases can occur in the context of ectopic CRH production, mainly by epithelial or nonepithelial NENs. In addition to ACTH/CRH secretion, gangliocytomas have also been observed in association with other hormone production. Vasopressin secretion by gangliocytomas can result in corticotroph hyperplasia and Cushing’s disease. There is no specific etiology responsible for the development of ECS; however, a subset of patients may be seen in the context of familial endocrine tumor syndromes. Treatment strategies for ECS aim at lowering cortisol levels and controlling tumor growth, with surgical resection being the preferred option when feasible. For unresectable or metastatic tumors, adjuvant treatments are considered.